MS Oral Therapies: Fingolimod, Dimethyl Fumarate, Teriflunomide
Multiple sclerosis is managed with acute treatment of relapses (high-dose IV methylprednisolone) plus long-term disease-modifying therapy (DMT). DMTs come in three delivery classes: injectable (interferon-beta, glatiramer), oral (fingolimod, dimethyl fumarate, teriflunomide), and infusion (natalizumab, ocrelizumab). This review focuses on the three oral agents — each has a distinct mechanism and a signature adverse-effect profile that is heavily tested.
Fingolimod
Fingolimod is an S1P (sphingosine-1-phosphate) receptor modulator that traps lymphocytes within lymph nodes, preventing their egress into the circulation and CNS. It holds the distinction of being the first oral DMT for MS. The two board-favorite adverse effects are bradycardia (a first-dose effect on cardiac S1P receptors, requiring first-dose cardiac monitoring) and macular edema, which threatens vision and warrants ophthalmologic monitoring.
Dimethyl fumarate
Dimethyl fumarate exerts anti-inflammatory effects through activation of Nrf2, a transcription factor that drives antioxidant and cytoprotective responses. Its characteristic, board-tested tolerability issues are flushing and GI side effects, which are common early in therapy. It can also cause lymphopenia, so periodic CBC monitoring is recommended; progressive multifocal leukoencephalopathy (PML) is an exceedingly rare, idiosyncratic complication seen almost only in the setting of prolonged, severe lymphopenia — not a routine signature toxicity like the PML risk classically associated with natalizumab.
Teriflunomide
Teriflunomide inhibits pyrimidine synthesis (via dihydroorotate dehydrogenase blockade), thereby limiting proliferation of rapidly dividing lymphocytes. Its two key safety concerns are teratogenicity — making it a poor choice in patients who may become pregnant — and hepatotoxicity, requiring monitoring of liver function.
High-yield
- MS DMTs fall into three routes: injectable (interferon-beta, glatiramer), oral (fingolimod, dimethyl fumarate, teriflunomide), and infusion (natalizumab, ocrelizumab).
- Acute MS relapse is treated with high-dose IV methylprednisolone (1 g/day x 3–5 days); DMT is for long-term relapse prevention, not the acute attack.
- Fingolimod = first oral DMT; think bradycardia (first-dose) + macular edema.
- Dimethyl fumarate = Nrf2 activation; signature effects are flushing + GI upset; can cause lymphopenia (monitor CBC).
- Teriflunomide = pyrimidine synthesis inhibitor; think teratogenicity + hepatotoxicity.
- Natalizumab is the DMT classically associated with PML risk (JC virus); PML with dimethyl fumarate is rare and tied to prolonged severe lymphopenia.
- MS diagnosis rests on dissemination in space and time (McDonald criteria); starting DMT is standard long-term management after diagnosis.
Pitfalls
- Confusing which adverse effect belongs to which drug — bradycardia/macular edema are fingolimod, flushing/GI are dimethyl fumarate, teratogenicity/hepatotoxicity are teriflunomide.
- Assuming a DMT treats the acute relapse — acute episodes require IV corticosteroids, while DMTs reduce future relapses.
- Overstating PML risk with dimethyl fumarate — PML is the hallmark concern with natalizumab; with DMF it is rare and generally requires prolonged, severe lymphopenia (hence CBC monitoring).
- Prescribing teriflunomide in a patient of childbearing potential without accounting for its teratogenicity.
- Overlooking that fingolimod requires attention to first-dose cardiac (bradycardia) and ocular (macular edema) effects.
Clinical pearls
- Fingolimod traps lymphocytes in lymph nodes by modulating S1P receptors — the immune cells can't get out to attack the CNS.
- A patient starting an oral MS drug who develops visual blurring — think fingolimod-associated macular edema.
- Monitor CBC on dimethyl fumarate: sustained severe lymphopenia is the setting for its rare PML risk.
- Check LFTs and pregnancy status before starting teriflunomide.
- Natalizumab is the DMT that classically screams PML (check JC virus antibody status).
Frequently asked
What are the three oral disease-modifying therapies for MS?
Fingolimod, dimethyl fumarate, and teriflunomide. They represent the oral class of DMTs, alongside injectable (interferon-beta, glatiramer) and infusion (natalizumab, ocrelizumab) options.
Which oral MS drug was the first available and what are its hallmark toxicities?
Fingolimod, an S1P receptor modulator, was the first oral DMT. Its signature adverse effects are first-dose bradycardia and macular edema.
How does dimethyl fumarate work, and what are its key adverse effects?
Dimethyl fumarate activates Nrf2 to produce anti-inflammatory and antioxidant effects. Its signature adverse effects are flushing and GI upset. It can also cause lymphopenia, so a CBC should be monitored; PML is an exceedingly rare complication tied to prolonged, severe lymphopenia rather than an expected class effect.
Why should teriflunomide be avoided in patients who may become pregnant?
Teriflunomide is teratogenic. It inhibits pyrimidine synthesis and also carries a risk of hepatotoxicity, so liver function and pregnancy status must be considered.
How does fingolimod's mechanism prevent CNS damage in MS?
It modulates S1P receptors to trap lymphocytes within lymph nodes, preventing their egress into the circulation and CNS, thereby limiting autoimmune attack on myelin.
What is the acute treatment of an MS relapse versus long-term management?
An acute relapse is treated with high-dose IV methylprednisolone (1 g/day for 3–5 days). Long-term management is a disease-modifying therapy, which may be oral, injectable, or infusion.
A patient on an oral MS drug develops flushing and GI side effects — which agent is most likely?
Dimethyl fumarate, whose common early tolerability issues are flushing and GI side effects.
Which MS drug is most strongly associated with PML?
Natalizumab, an infusion DMT, carries the classic, well-tested PML risk (linked to JC virus). Among the oral agents, PML is only rarely reported with dimethyl fumarate and typically in the setting of prolonged, severe lymphopenia.
Turn this into reasoning you can use on exam day — practice MS Oral Therapies on branching cases where your decisions shape the patient.